To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Recruiting · NCT06752681 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-07-22 | NCT06752681 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Day One Biopharmaceuticals, Inc. | 7 |
11 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Site: 001-039 | New York | United States | 1 |
| Site: 001-057 | San Antonio | United States | 1 |
| Site: 001-058 | New Haven | United States | 1 |
| Site: 001-059 | Grand Rapids | United States | 1 |
| Site: 001-060 | Avon | United States | 1 |
| Site: 001-064 | Sarasota | United States | 1 |
| Site: 001-065 | Nashville | United States | 1 |
| Site: 001-069 | Houston | United States | 1 |
| Site: 001-073 | Oklahoma City | United States | 1 |
| Site: 011-005 | Toronto | Canada | 1 |
| Site: 011-013 | Vancouver | Canada | 1 |